TABLE 2.
Gastrointestinal and Hepatic Characteristics Among Patients With Acute COVID-19 and MIS-C
| Variable | All Patients With GI Involvement (N = 500) | Acute COVID-19 Patients With GI Involvement (N = 307) | MIS-C Patients With GI Involvement (N = 193) | P |
|---|---|---|---|---|
| GI symptoms, n (%) | ||||
| Any GI symptom | 411 (82.2) | 239 (77.9) | 172 (89.1) | 0.001 |
| Nausea/vomiting | 263 (52.6) | 142 (46.3) | 121 (62.7) | 0.0003 |
| Abdominal pain | 196 (39.2) | 101 (32.9) | 95 (49.2) | 0.0003 |
| Loss of appetite | 155 (31.0) | 89 (29.0) | 66 (34.2) | 0.22 |
| Diarrhea | 145 (29.0) | 64 (20.8) | 81 (42.0) | <0.0001 |
| Constipation | 10 (2.0) | 10 (3.3) | 0 (0) | 0.01 |
| Hematochezia | 7 (1.4) | 5 (1.6) | 2 (1.0) | 0.71 |
| Hematemesis | 2 (0.4) | 2 (0.7) | 0 (0) | 0.53 |
| Jaundice | 1 (0.2) | 1 (0.3) | 0 (0) | >0.99 |
| Admission diagnosis, n (%) | ||||
| Appendicitis | 29 (5.8) | 27 (8.8) | 2 (1.0) | 0.0003 |
| Mesenteric adenitis | 4 (0.8) | 2 (0.7) | 2 (1.0) | 0.64 |
| Pancreatitis | 3 (0.6) | 3 (1.0) | 0 (0) | 0.29 |
| Elevated liver enzymes, n (%) | ||||
| AST | 158 (31.6) | 77 (25.1) | 81 (42.0) | <0.0001 |
| ALT | 121 (24.2) | 59 (19.2) | 62 (32.1) | 0.001 |
| INR | 120 (24.0) | 34 (11.1) | 86 (44.6) | <0.0001 |
| Total bilirubin | 67 (13.4) | 42 (13.7) | 25 (13.0) | 0.82 |